Skip to main content

Published locations for FDA OKs nivolumab after surgery for esophageal or GEJ cancer: Practice-changing use of immunotherapy

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA OKs nivolumab after surgery for esophageal or GEJ cancer: Practice-changing use of immunotherapy

User login

  • Reset your password
  • /content/fda-oks-nivolumab-after-surgery-esophageal-or-gej-cancer-practice-changing-use-immunotherapy
  • /familypracticenews/article/240466/gastroenterology/fda-oks-nivolumab-after-surgery-esophageal-or-gej
  • /fedprac/article/240466/gastroenterology/fda-oks-nivolumab-after-surgery-esophageal-or-gej-cancer
  • /internalmedicinenews/article/240466/gastroenterology/fda-oks-nivolumab-after-surgery-esophageal-or
  • /fedprac/avaho/article/240466/gastroenterology/fda-oks-nivolumab-after-surgery-esophageal-or-gej
  • /jcomjournal/article/240466/gastroenterology/fda-oks-nivolumab-after-surgery-esophageal-or-gej-cancer
  • /internalmedicine/article/240466/gastroenterology/fda-oks-nivolumab-after-surgery-esophageal-or-gej
  • /familymedicine/article/240466/gastroenterology/fda-oks-nivolumab-after-surgery-esophageal-or-gej